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siveness to therapy and the number of disease relapses.
After multiple relapses, this lymphoma becomes refrac-
tory to standard therapies. Thus the median survival is
dramatically shortened to 24 to 26 months. Relapsed, re-
fractory low-grade lymphoma (RRLGNHL) is a common
disease progression and the focus of multiple studies in
the search for more effective therapies. Rituximab is an
anti-CD20 immunotherapy approved for the treatment
of RRLGNHL. It is marginally more effective in refrac-
tory cases than salvage therapy, but has a less severe side
effect profile. OBJECTIVE: To estimate the cost-effec-
tiveness ratio of rituximab in the treatment of RRLGNHL.
METHODS: The study utilized a societal perspective
with a two-year time horizon and an annual discount
rate of 3%. Outcomes data and their probabilities were
abstracted from randomized controlled trials for ritux-
imab and DHAP in RRLGNHL patient populations. Di-
rect medical costs, drug costs and health-state related
utilities were abstracted from other studies, standard
Medicare reimbursement rates and the Red Book. An in-
cremental cost-effectiveness ratio (ICE) was used to esti-
mate the effectiveness of rituximab compared to DHAP.
RESULTS: The study found an ICE ratio of $58,166 per
quality adjusted life-year saved. The model was found to
be sensitive to the medication costs, medication response
rates and the cost of autologous bone marrow transplan-
tation. CONCLUSION: Based on the findings, rituximab
appears to be a marginally cost-effective alternative for
RRLGNHL. Relative drug costs and response rates must
be considered before a conclusion can be drawn for a
specific institution.
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The aim of the trial was to compare using cost-effective-
ness analysis two schemes of chemotherapy in advanced
breast cancer as the first line of therapy. METHODS: Pa-
tients were randomly assigned to chemotherapy. Arm A:
standard scheme CAF (30 pts), and arm B: scheme TAD
(23 pts), 126 cycles. Effect was estimated after finishing 6
cycles. Results: CR or PR was seen in 78% of cases
(TAD) and 60% of cases (CAF). Stabilization of the pro-
cess was 13% and 23%, progression of the process was
9% and 17% accordingly. The cost of each cycle is as
follows: hospital expenditures, cost of diagnostic and
laboratory tests and expenses on medicine. The cost of 6
cycles per patient is 9845 USD (TAD) and 2140 USD
(CAF). But high level of effectiveness of this treatment
provides repayment that is demonstrated in table:
As a result of cost-effectiveness analysis the analysis of
clinical decisions was made and decision tree was built.
The final calculation of cost/ effectiveness index showed
advantages of TAD scheme compared to CAF scheme:
So, the advantage of the preliminary data of TAD scheme
according to rational utilization makes 37% compared to
CAF scheme.
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Epoetin alpha (EPO) usage increased five-fold during the
past three years at The University of Texas MD Ander-
son Cancer Center (UTMDACC). EPO has been shown
to be safe and might be considered more effective than
treatment with red blood cell infusions for patients with
chemotherapy-induced anemia. OBJECTIVE: To deter-
mine patterns of EPO usage in cancer patients and to
evaluate physicians’ adherence to proposed clinical guide-
lines. METHODS: We conducted a retrospective data-
base analysis for all in-patient EPO prescriptions processed
at the UTMDACC from March 1 to April 30 of 1999.
Patients receiving EPO during this period were each fol-
lowed throughout the course of their drug therapy. Data
was extracted for these patients using a pharmacy elec-
tronic database. The following information was coded:
administration dates, hemoglobin (Hgb) levels, units ad-
ministered, drug (EPO) cost, disease category, age, gen-
der, ethnic group, and residence. Based on the Hgb levels,
the data was coded into two groups, within or outside
proposed EPO guidelines and analyzed to evaluate pat-
terns of drug use. RESULTS: A total of 119 patients
(52% males) were identified with an average age of 57
years (range 9–81 years). Total drug cost per month for
all patients was $100,643. Around 35% (n  41) of pa-
Scheme
Average value
(USD)
Value of effective ChT (USD)
Remission Progression
TAD 9845 7705 13843
CAF 2140 1214 4207
It is according
4 cycles 7–8 cycles
Effect
Cost/effectiveness index
TAD CAF
General effectiveness 0,0006 0,0040
Remission
0,003
0,0137
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tients responded to the drug therapy based on Hgb levels.
It was determined that in 28.5% (n  33) of the patients,
physicians did not follow the proposed guidelines. Of
these patients 58% (n  19) were either non-responders
or questionable responders to drug therapy. Of those that
were determined as outside the proposed guidelines,
$404.99/patient was spent in drug cost for those consid-
ered as non-responders or questionable responders,
whereas, $312.54/patient was spent on patients that re-
sponded to the therapy. CONCLUSION: An intervention
by a pharmacist to monitor drug therapy could reduce
drug cost and improve clinical outcomes. Further research
with a larger sample size is required to validate the re-
sults.
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The psychosocial implications of cancer and its treat-
ments are well recognized. In NSCLC, many patients are
diagnosed at an advanced stage with substantial impair-
ment of QoL. While psychometric-based measures allow
the assessment of patients in a descriptive profile of one
or more QoL domains, utility measures allow the expres-
sion of the overall experience of QoL in a single number
that represents patient preferences for different levels of
QoL. However, the scientific validity of QoL and utility
assessments is determined by the reliability and validity
of the measures used. OBJECTIVES: To identify utility
and psychometric-based instruments used in NSCLC and
compare evidence in support of their validity, reliability
and responsiveness. METHODS: We conducted a search
of MEDLINE, EMBASE and within our Information Re-
sources Centre from 1985 to date using various terms
icluding NSCLC, QoL and utilities. RESULTS: Instru-
ments were selected for review if they had been devel-
oped or used in a study population of which at least 20%
were NSCLC patients. The search and selection yielded
26 original studies in which 4 utility measures (TTO,
TrTO, HUI and EQ-5D) and 12 psychometric-based
health profiles such as the SF-36, FACT-G and the
EORTC-QLQ were applied. Our review of published
data revealed striking differences between measures in
terms of the coverage of QoL conceptual domains and
psychometric properties. Compared to health profiles,
relatively scant evidence was found in support of the psy-
chometric validity of utility measures. CONCLUSION:
Findings from this review suggest a need for further vali-
dation of existing utility measures in order to enhance the
collection of scientifically valid preference-weighted QoL
data during studies of patients with NSCLC.
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In light of the current emphasis in the health care envi-
ronment on both minimising cost and maximising favor-
able outcomes, it makes good economic sense to incorpo-
rate quality of life (QOL) assessment in order to sensitively
evaluate the impact of interventions on individual’s well
being. The aim of the study was to determine to what ex-
tent QOL is influenced by the Hb increase and if, in this
way, patients who showed improved Hb levels also
showed improvements in QOL domains. 26 anemic can-
cer patients undergoing chemotherapy with initial Hb
levels  9 g/dL, were analyzed. Exclusion criteria were:
uncontrolled hypertension, serum-ferritin 50 ug/ml,
acute infection, comorbidities that could contribute to
the anemia, acute or chronic bleeding and inability to un-
derstand the questionnaire. Response was defined as an
increase over baseline by greater that 1 g/dL. rhEPO
treatment was given three times weekly, 150 IU/kg s.c.
during 8 weeks. QOL was assessed using the Functional
Assessment Cancer Therapy, and measured at baseline
and after 2, 4 and 8 weeks. RESULTS: Reliability analy-
sis (Chronbach’s alpha) was satisfactory. All the patients
showed improvement in Hb level 1 g/dL. Only 1 pa-
tient required transfusion. The questionnaire data dem-
onstrated that increased Hb levels were associated with
improved QOL outcomes. When scores at baseline and at
8 weeks were compared (paired sample t-test), the differ-
ences were statistically significant (P  01) for the physi-
cal well-being (WB), social/family WB and functional WB
domain. The difference also reached highly statistical sig-
nificance (P  0.001) for anemia and fatigue subscales.
CONCLUSION: In our sample, treatment with rhEPO
can safely increase Hb levels, decreasing transfusion re-
quirements. Simultaneously, patients QOL was im-
proved, and the difference from baseline to final assess-
ment scores reached statistical significance. This study
encourages the concept of QOL as a meaningful endpoint
for determining which treatments have the optimal ef-
fects from the patient’s perspective.
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Although race has been associated with differences in the
utilization and costs of medical services for a variety of
conditions, no study has examined racial differences in
